Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA15 5th Dose in Healthy Participants ≥7 Years of Age
NCT07500506Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of VLA15 in Lyme disease, sponsored by Pfizer. Started Apr 2026; status: recruiting.
02
Drugs
VLA15
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT07500506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500506.